Dual-energy computed tomography for monitoring the effect of urate-lowering therapy in gouty arthritis

Int J Rheum Dis. 2015 Nov;18(8):880-5. doi: 10.1111/1756-185X.12634. Epub 2015 Jul 28.

Abstract

Objective: To investigate the relationships between changes in serum urate levels and dual-energy computed tomography (DE-CT) results during urate-lowering therapy (ULT) and to investigate the effects of treatment duration and drugs on changes in DE-CT results.

Methods: Forty-four patients diagnosed with gout were enrolled in this investigation. DE-CT was conducted on the foot at baseline and the end of follow-up (6-24 months). Crystals were classified as: (i) L, number of large crystals with diameter ≥ 3 mm; (ii) S, number of small crystals with diameter < 3 mm; (iii) T, total number of crystals; and (iv) Vmax, volume of the maximal crystal.

Results: Number of urate crystals (L, S as well as T) and Vmax decreased significantly through ULT. Significant decrease of urate crystal numbers and/or Vmax was observed in different follow-up groups, and the decrease in serum urate levels was positively related to the decrease of T (r = 0.43, P = 0.04) and Vmax (r = 0.63, P = 0.04). Moreover, analysis of covariance results demonstrated significant effects of treatment duration and serum urate levels on results of DE-CT.

Conclusion: Both urate crystal numbers and Vmax decreased significantly during ULT. Additionally, ULT duration and serum urate levels had significant effects on the decrease of Vmax and number of large crystals measured by DE-CT.

Keywords: dual-energy computed tomography; gouty arthritis; urate-lowering therapy; uric acid.

Publication types

  • Clinical Study
  • Research Support, Non-U.S. Gov't

MeSH terms

  • Adult
  • Aged
  • Arthritis, Gouty / blood
  • Arthritis, Gouty / diagnostic imaging*
  • Arthritis, Gouty / drug therapy*
  • Biomarkers / blood
  • Crystallization
  • Drug Monitoring / methods*
  • Female
  • Foot Bones / diagnostic imaging*
  • Foot Bones / drug effects*
  • Foot Bones / metabolism
  • Gout Suppressants / therapeutic use*
  • Humans
  • Male
  • Middle Aged
  • Predictive Value of Tests
  • Tomography, X-Ray Computed*
  • Treatment Outcome
  • Uric Acid / blood*

Substances

  • Biomarkers
  • Gout Suppressants
  • Uric Acid